Genedrive Plc - Company Profile
Powered by 
All the sales intelligence you need on Genedrive Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Genedrive Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Genedrive Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Genedrive Plc (Genedrive) formerly Epistem Holdings Plc specializes in the development of point-of-care molecular diagnostic platforms. The company's major activities include the creation of novel tests for various clinical indications such as genotyping, pathogen detection, and infectious disease detection. The company's major products include the Genedrive MT-RNR1 ID kit, used for detecting antibiotic-induced hearing loss in neonates, and the Genedrive CYP2C19 ID kit, a rapid point-of-care test for CYP2C19 genotyping. The company's products are primarily used in healthcare settings, particularly in emergency medicine, for patient stratification and disease detection. The company provides its products in North America, Asia Pacific, Europe, Middle East and Africa (EMEA) region through its distribution partners. Genedrive is headquartered in Manchester, the UK.
Headquarters
United Kingdom
Address
48 Grafton Street, Manchester, England, M139XX
Website
www.genedriveplc.com
Telephone
44 161 9890245
No of Employees
43
Industry
Medical Equipment
Ticker Symbol & Exchange
GDR (LON)
Revenue (2025)
$1.2M
90.4%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
26.1%
(2025 vs 2024)
Market Cap*
$27.7M
Net Profit Margin (2025)
XYZ
61.2%
(2025 vs 2024)
* As of and is in US$
Genedrive Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Genedrive HCV ID Kit | Genedrive |
| Genedrive MT-RNR1 ID Kit | |
| Genedrive 96 SARS-CoV-2 Kit | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Others | In December, the company sought for the approval to sell its rapid molecular test, Genedrive COV19-ID kit in the UK. |
| 2021 | Regulatory Approval | In April, the company received approval from the Indian Council of Medical Research for Genedrive 96 SARS-CoV-2 Kit. |
| 2021 | Contracts/Agreements | In March, the company entered into an agreement with Mountain Horse Solutions, to distribute the company's military pathogen detection assays in the US. |
Competitor Comparison
| Key Parameters | Genedrive Plc | GSK plc | GenMark Diagnostics Inc | Immunodiagnostic Systems Holdings Ltd | Tiziana Life Sciences Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United States of America | United Kingdom | Bermuda |
| City | Manchester | London | Carlsbad | Tyne and Wear | Hamilton |
| State/Province | England | England | California | Tyne and Wear | - |
| No. of Employees | 43 | 68,629 | - | 16 | 8 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gino Miele, Ph.D. | Director; Chief Executive Officer; Chief Scientific Officer | Executive Board | 2024 | 55 |
| Russell Shaw | Director; Chief Financial Officer | Executive Board | 2022 | 46 |
| Ian Gilham, Ph.D. | Chairman | Non Executive Board | 2015 | 65 |
| Chris Yates | Director | Non Executive Board | 2018 | 51 |
| Thomas Lindsay | Director | Non Executive Board | 2018 | 68 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer